Open an account

Immatics NV

IMTX · NASDAQ

$7.51+$0.46 (+6.52%)TodayMarket closed ·
Prev close $7.05

About IMTX

Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 285 full-time employees. The company went IPO on 2020-07-02. The firm is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The firm develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.

Employees
285
Headquarters
Tuebingen, Baden-Wuerttemberg
Listed
Jul 2, 2020
Sector
Health Care
Industry
Biotechnology
Website
immatics.com

IMTX key statistics

Market cap
1.12B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
990.40K
Volume
1.26M
Open price
$7.07
High today
$7.61
Low today
$6.94
52 Week high
$12.41
52 Week low
$6.65

Immatics NV (IMTX) at a glance

As of Oct 20, 2026, Immatics NV (IMTX) shares are priced at $7.51, giving the company a market cap of 1.12B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $6.94 and $7.61. The current price is 8.3% above the day's low and 1.2% below its high.

Volume so far is 1.26M shares, above the average of 990.40K shares a day.

Over the past year Immatics NV has ranged from $6.65 to $12.41, and now sits 15% of the way up that range.

Immatics NV met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.46 per share against an estimate of -$0.4352.

The average analyst price target is $17.95, 139.0% above the current price, from 6 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 6 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $17.95
Low
$11.92
Now
$7.51
High
$26.25

IMTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 80.2% on average.

  1. Q3 FY24: reported -$0.08 per share against an estimate of -$0.2601
  2. Q4 FY24: reported $0.43 per share against an estimate of -$0.3392
  3. Q1 FY25: reported -$0.33 per share against an estimate of -$0.3315
  4. Q2 FY25: reported -$0.58 per share against an estimate of -$0.3264
  5. Q3 FY25: reported -$0.42 per share against an estimate of -$0.3978
  6. Q4 FY25: reported -$0.29 per share against an estimate of -$0.3838
  7. Q1 FY26: reported -$0.43 per share against an estimate of -$0.41
  8. Q2 FY26: reported -$0.46 per share against an estimate of -$0.4352

IMTX news

  • Press releaseGlobe Newswire

    Immatics Announces Second Quarter 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Immatics Announces First Quarter 2026 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Immatics Announces Full Year 2025 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Immatics Announces Third Quarter 2025 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Immatics Announces Second Quarter 2025 Financial Results and Business Update

  • Press releaseGlobe Newswire

    Immatics Announces First Quarter 2025 Financial Results and Business Update

  • Press releaseBusiness Wire

    Clear Street Launches Healthcare & Biotechnology Equity Research

Similar companies

Companies in the same industry as Immatics NV

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.